Susquehanna International Group LLP Acquires 172,828 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO)

Susquehanna International Group LLP increased its position in shares of Alpha Teknova, Inc. (NASDAQ:TKNO - Free Report) by 472.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 209,409 shares of the company's stock after purchasing an additional 172,828 shares during the quarter. Susquehanna International Group LLP owned approximately 0.39% of Alpha Teknova worth $1,749,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TKNO. Nkcfo LLC acquired a new position in Alpha Teknova during the 4th quarter valued at about $501,000. Invesco Ltd. bought a new stake in Alpha Teknova during the 4th quarter worth approximately $9,236,000. Raymond James Financial Inc. acquired a new stake in shares of Alpha Teknova during the fourth quarter worth $716,000. Barclays PLC bought a new stake in shares of Alpha Teknova in the fourth quarter valued at about $132,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Alpha Teknova during the 4th quarter worth approximately $94,000. 13.81% of the stock is currently owned by institutional investors and hedge funds.

Alpha Teknova Stock Up 0.5%

Shares of NASDAQ TKNO traded up $0.03 during trading hours on Friday, hitting $6.54. The company had a trading volume of 70,890 shares, compared to its average volume of 384,281. The company has a quick ratio of 3.94, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm's 50 day moving average is $5.83 and its 200-day moving average is $7.10. Alpha Teknova, Inc. has a 1-year low of $1.16 and a 1-year high of $10.37. The stock has a market capitalization of $349.50 million, a P/E ratio of -8.84 and a beta of 0.50.

Alpha Teknova (NASDAQ:TKNO - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. Alpha Teknova had a negative return on equity of 35.30% and a negative net margin of 87.17%. The company had revenue of $9.60 million during the quarter, compared to analysts' expectations of $9.41 million. On average, analysts expect that Alpha Teknova, Inc. will post -0.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Craig Hallum began coverage on Alpha Teknova in a research report on Monday, February 10th. They issued a "buy" rating and a $12.00 target price on the stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.